[
  {
    "ts": null,
    "headline": "FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug",
    "summary": "REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.",
    "url": "https://finnhub.io/api/news?id=279ae4e9e3d64ab9320a467eefd340d9b15cec113d6f2100dcf537bdac07bcfc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751548560,
      "headline": "FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug",
      "id": 135736146,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.",
      "url": "https://finnhub.io/api/news?id=279ae4e9e3d64ab9320a467eefd340d9b15cec113d6f2100dcf537bdac07bcfc"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
    "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
    "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751543043,
      "headline": "Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma",
      "id": 135735538,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Lynozyfic can be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.",
      "url": "https://finnhub.io/api/news?id=7094989b37f7b267947e1092daa23c9e4b17471a9fea1376c7e624f1441b13b0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals - Lynozyfic Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma",
    "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic to treat adult patients with relapsed or refractory ...",
    "url": "https://finnhub.io/api/news?id=ead9800e59cc891cda77046984ec041e4c40722de02aacd13794400459fbd07a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751539100,
      "headline": "Regeneron Pharmaceuticals - Lynozyfic Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma",
      "id": 135734600,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN - Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic to treat adult patients with relapsed or refractory ...",
      "url": "https://finnhub.io/api/news?id=ead9800e59cc891cda77046984ec041e4c40722de02aacd13794400459fbd07a"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this […]",
    "url": "https://finnhub.io/api/news?id=73c3bdc595bced8c3e275c5faaac5fc862aaffe78e6966a8a76e13b1df92e2a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751525254,
      "headline": "Regeneron Pharmaceuticals (REGN) and Sanofi Announce Approval of Dupixent® By US FDA",
      "id": 135723475,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi announced that the US FDA approved Dupixent® (dupilumab) for the treatment of adult patients with bullous pemphigoid (BP). The approval for bullous pemphigoid brings a novel treatment approach to patients and their caregivers. Also, this […]",
      "url": "https://finnhub.io/api/news?id=73c3bdc595bced8c3e275c5faaac5fc862aaffe78e6966a8a76e13b1df92e2a0"
    }
  }
]